Vertex Pharmaceuticals Incorporated
NASDAQ:VRTXBiotechnology
-$6.43 today
- Market cap
- $136.01B
- Beta
- 0.31
- P/E (TTM)
- 26.5
- EPS (TTM)
- $17.07
Volume 1.29M
Average 1.26M
VRTX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Vertex Pharmaceuticals IncorporatedNASDAQ: VRTX
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income grows, but more slowly than its trailing trend
Q2 FY2026 net income of $1.1B rose 6.5% year over year, behind the +21.1% change in trailing-twelve-month net income. Sequentially, it rose 6.6% from the prior quarter. Over 3 fiscal years it compounded at +6.0% a year.
Context
- Net income amounted to 32.7% of revenue in FY2025, up 27.9 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 21 analysts of $4.62B (+16.7%) for the fiscal year ending Dec 2026, a slowdown from the +838.1% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $1.1B+6.6% QoQ
- Last fiscal yearDec 2025
- $3.95B+838.1% YoY
- LTMJun 2026
- $4.41B+21.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +6.5% | +13.5% | +7.0 pp |
| 1 year | +838.1% | +16.7% | -821.3 pp |
| 3-year CAGR | +6.0% | +15.1% | +9.1 pp |
| 5-year CAGR | +17.1% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 3.95B USD
- Year-over-year change
- +838.1%
- 4-year CAGR
- +14.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.95B | +838.1% |
| FY2024 | 2024-12-31 | (535.6M) | -114.8% |
| FY2023 | 2023-12-31 | 3.62B | +9.0% |
| FY2022 | 2022-12-31 | 3.32B | +41.8% |
| FY2021 | 2021-12-31 | 2.34B | — |
Net Income vs competitors
How VRTX compares with its peers on the latest reported figures
- VRTX's LTM Jun 2026 net income of $4.41B is the 2nd largest of the 11 companies compared; the peer median is $270.78M.
- Its year-over-year change of +21.1% is the 5th highest of 11, against a peer median of +3.0%.
- Net income amounts to 34.9% of revenue for VRTX, versus a peer median of 55.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $27.6B | +3808.4% | +35.1% | 2.7% | |
| LTM Jun 2026 | $4.41B | +21.1% | +6.0% | 34.9% | |
| LTM Jun 2026 | $807.99M | +353.2% | — | 16.8% | |
| LTM Jun 2026 | $695.45M | -11.4% | +14.4% | 97.5% | |
| LTM Mar 2026 | $608.92M | +10.8% | -6.7% | 91.0% | |
| LTM Sep 2026 | $546.15M | +113.1% | +12.2% | 56.9% | |
| LTM Mar 2026 | $500.92M | -4.8% | +3.1% | 757.9% | |
| LTM Sep 2026 | $456.14M | -6.6% | -3.6% | 1812.1% | |
| LTM Jun 2026 | $85.43M | -78.6% | -34.8% | 54.7% | |
| LTM Mar 2026 | $65.06M | +126.2% | +0.5% | 3.0% | |
| LTM Jun 2026 | $38.38M | -106.1% | — | 3.8% | |
| Peer median (excluding VRTX) | $270.78M | +3.0% | +1.8% | 55.8% | |
Competitors are the stored peer set for VRTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 2.34B | 3.32B | 3.62B | (535.6M) | 3.95B |
| Depreciation & Amortization | 125.6M | 148.3M | 181.3M | 207.2M | 209.8M |
| Deferred Income Tax | (154.6M) | (275.9M) | (536.5M) | (348.8M) | (510.8M) |
| Stock-Based Compensation | 441.4M | 491.3M | 581.2M | 698.5M | 685.9M |
| Change in Working Capital | (105.2M) | 340.8M | (265.7M) | (514.8M) | (1.2B) |
| Accounts Receivables | (274.7M) | (358.6M) | (84.1M) | (99.3M) | (347.3M) |
| Inventory | (92.8M) | (136.4M) | (322.9M) | (517.3M) | (524.2M) |
| Accounts Payables | 31.9M | 120.8M | 48.7M | 49.5M | 36.8M |
| Other Working Capital | 230.4M | 715M | 92.6M | 52.3M | (364.4M) |
| Other Non-Cash Items | (5.8M) | 103.4M | (42.6M) | 900K | 492.4M |
| Operating Cash Flow | 2.64B | 4.13B | 3.54B | (492.6M) | 3.63B |
| Capital Expenditures | (235M) | (204.7M) | (258.4M) | (297.7M) | (437.6M) |
| Acquisitions (Net) | 77M | (295.9M) | 0 | 0 | 0 |
| Purchases of Investments | (605.2M) | (692.7M) | (3.79B) | (7.7B) | (6.4B) |
| Sales of Investments | 499.3M | 920M | 934.2M | 4.47B | 5.91B |
| Other Investing Activities | (77M) | (47.8M) | (89M) | (241.7M) | (24.7M) |
| Investing Cash Flow | (340.9M) | (321.1M) | (3.14B) | (3.77B) | (945.4M) |
| Debt Repayment | (18.7M) | (85.5M) | (44.9M) | (33.6M) | (5.4M) |
| Common Stock Issued | 102M | 186.3M | 134.6M | 114.6M | 127.7M |
| Common Stock Repurchased | (1.43B) | (172M) | (427.6M) | (1.18B) | (2.02B) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (130.2M) | 3.5M | (224.3M) | (398.8M) | (366.2M) |
| Financing Cash Flow | (1.48B) | (67.7M) | (562.2M) | (1.49B) | (2.26B) |
| Effect of Forex Changes | (13.4M) | (29.2M) | 26.9M | (42.6M) | 90.9M |
| Net Change in Cash | 811.2M | 3.71B | (139.7M) | (5.8B) | 515.6M |
| Free Cash Flow | 2.41B | 3.93B | 3.28B | (790.3M) | 3.19B |
Vertex Pharmaceuticals Incorporated
NASDAQ:VRTX
Intrinsic Alpha fair value
Locked
Current Price
$536.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.